FDA Extends Covid-19 Vaccine Meeting to Allow Public Input - COVID-19 Clinical Trial
Breaking News | COVID-19

FDA Extends Covid-19 Vaccine Meeting to Allow Public Input

The US Food and Drug Administration has added extra time to a daylong meeting Thursday of its vaccine advisers, who are gathering to discuss a potential coronavirus vaccine.The meeting will now include at least an hour and a half for public input, according to an agenda posted online. The agency has been working to boost faith in the regulatory process after President Donald Trump pushed for a vaccine by Election Day, feeding fears that the federal government was cutting corners to rush a vaccine to market for political reasons.The meeting of the Vaccines and Related Biological Products Advisory Committee will also stream live on YouTube — an unusual social media performance for an typically obscure gathering of experts on immunology, molecular biology, infectious diseases and biostatistics.

While vaccines can be controversial — thanks to an increasingly loud, if still small, vaccine skeptic movement — this particular group of vaccines is coming under enormous scrutiny.One or more of these vaccines are the best hope for rescuing humanity from the nearly year-long pandemic that’s infected more than 40 million people globally and killed more than 1.1 million of them. In the US, the count is 8.2 million cases and 220,000 deaths.

Study Finds AstraZeneca’s COVID-19 Vaccine Follows Genetic Instructions

AstraZeneca’s AZN.L Oxford COVID-19 vaccine accurately follows the genetic instructions programmed into it by its developers to successfully provoke a strong immune response, according to a detailed analysis carried out by independent UK scientists. “The vaccine is doing everything we expected and that is only good news in our fight against the illness,” said David Matthews, an expert in virology from Bristol University, who led the research.

AstraZeneca, which is developing the vaccine with Oxford University researchers, is seen as a frontrunner in the race to produce a vaccine to protect against COVID-19. The first data from late-stage large-scale clinical trials being conducted in several countries around the world, including Brazil, the United States and Britain, are expected to be released before the end of the year.

Share this:

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.